Dmitry Gryadunov

Prof. Dr. Dmitry Gryadunov

Engelhardt Institute of Molecular Biology, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
ENElena Yu. Nosova
Elena Yu. Nosova
EKElena V. Kulagina
Elena V. Kulagina
OAOlga V. Antonova
Olga V. Antonova
LALiaisan R. Arslanbaeva
Liaisan R. Arslanbaeva
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
Objectives: To study the isolates with acquired resistance to bedaquiline and linezolid that were obtained from patients enrolled in a clinical study of a novel therapy regimen for drug-resistant TB in Moscow, Russia. Methods: Linezolid resistance was detected using MGIT 960 with a critical concentration of 1 mg/L. The MIC of bedaquiline was determined using the proportion method. To identify genetic determinants of resistance, sequencing of the mmpR (Rv0678), atpE, atpC, pepQ, Rv1979c, rrl, rplC and rplD loci was performed. Results: A total of 85 isolates from 27 patients with acquired resistance to linezolid and reduced susceptibility to bedaquiline (MIC ≥0.06 mg/L) were tested. Most mutations associated with a high MIC of bedaquiline were found in the mmpR gene. We identified for the first time two patients whose clinical isolates had substitutions D28N and A63V in AtpE, which had previously been found only in in vitro-selected strains. Several patients had isolates with elevated MICs of bedaquiline prior to treatment; four of them also bore mutations in mmpR, indicating the presence of some hidden factors in bedaquiline resistance acquisition. The C154R substitution in ribosomal protein L3 was the most frequent in the linezolid-resistant strains. Mutations in the 23S rRNA gene (g2294a and g2814t) associated with linezolid resistance were also found in two isolates. Heteroresistance was identified in ∼40% of samples, which reflects the complex nature of resistance acquisition. Conclusions: The introduction of novel drugs into treatment must be accompanied by continuous phenotypic susceptibility testing and the analysis of genetic determinants of resistance.

1 July 2001 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
VMVladimir Mikhailovich
Vladimir Mikhailovich
SLSergey Lapa
Sergey Lapa
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
ASAlexander Sobolev
Alexander Sobolev
BSBoris Strizhkov
Boris Strizhkov
AMAndrei Mirzabekov
Andrei Mirzabekov
Three new molecular approaches were developed to identify drug-resistant strains of Mycobacterium tuberculosis using biochips with oligonucleotides immobilized in polyacrylamide gel pads. These approaches are significantly faster than traditional bacteriological methods. All three approaches—hybridization, PCR, and ligase detection reaction—were designed to analyze an 81-bp fragment of the gene rpoB encoding the β-subunit of RNA polymerase, where most known mutations of rifampin resistance are located. The call set for hybridization analysis consisted of 42 immobilized oligonucleotides and enabled us to identify 30 mutant variants of the rpoB gene within 24 h. These variants are found in 95% of all mutants whose rifampin resistance is caused by mutations in the 81-bp fragment. Using the second approach, allele-specific on-chip PCR, it was possible to directly identify mutations in clinical samples within 1.5 h. The third approach, on-chip ligase detection reaction, was sensitive enough to reveal rifampin-resistant strains in a model mixture containing 1% of resistant and 99% of susceptible bacteria. This level of sensitivity is comparable to that from the determination of M. tuberculosis drug resistance by using standard bacteriological tests.

1 July 2005 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
VMVladimir Mikhailovich
Vladimir Mikhailovich
SLS. Lapa
S. Lapa
NRN. Roudinskii
N. Roudinskii
MDM. Donnikov
M. Donnikov
AMA. Mirzabekov
A. Mirzabekov
A molecular approach was developed to identify drug-resistant strains of Mycobacterium tuberculosis by means of biochips with oligonucleotides immobilised in polyacrylamide gel pads. The technique was based on multiplex PCR, followed by hybridisation on an oligonucleotide microarray, and detected > 95% of rifampicin-resistant and c. 80% of isoniazid-resistant M. tuberculosis isolates within 12 h. In total, 220 drug-resistant isolates and 131 clinical samples were tested using biochips. The sensitivity and specificity of the developed method were comparable with those of standard bacteriological testing of M. tuberculosis drug resistance.

5 June 2008 in BioEssays
Verified
Journal Article
Closed access
PDF file
VMVladimir Mikhailovich
Vladimir Mikhailovich
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
AKAlexander Kolchinsky
Alexander Kolchinsky
AMAlexander Makarov
Alexander Makarov
AZAlexander Zasedatelev
Alexander Zasedatelev

1 February 2008 in BioTechniques
Verified
Journal Article
Open access
DKDmitry A. Khodakov
Dmitry A. Khodakov
NZNatalia V Zakharova
Natalia V Zakharova
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
FFFelix P. Filatov
Felix P. Filatov
AZAlexander S. Zasedatelev
Alexander S. Zasedatelev
VMVladimir Mikhailovich
Vladimir Mikhailovich
We describe a novel microarray-based approach for simultaneous identification and quantification of human immunodeficiency virus type 1 (HIV-1) and hepatitis B and C viruses (HBV and HCV) in donor ...

25 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Boris Leonidovich ShaskolskiyBoris Leonidovich Shaskolskiy
Boris Leonidovich Shaskolskiy
EDEkaterina Dementieva
Ekaterina Dementieva
Ilya KandinovIlya Kandinov
Ilya Kandinov
MFMarina Filippova
Marina Filippova
NPNatalia Petrova
Natalia Petrova
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
The goal of this work was to study the phenotypic susceptibility and resistance determinants of N. gonorrhoeae isolates to beta-lactam antimicrobials (benzylpenicillin and ceftriaxone). A total of 522 clinical isolates collected in Russia in 2015–2017 were analysed for susceptibility using the agar dilution method. DNA loci involved in antimicrobial resistance were identified using DNA microarray analysis and sequencing. Resistance to benzylpenicillin remained high, with 7.7% of isolates resistant (MICpen > 1 mg/L) and 47.5% of isolates showing intermediate susceptibility (MICpen = 0.12–1 mg/L). The most frequent resistance determinant (72.4% isolates) was the Asp345 insertion in penA, both as a single mutation and in combination with other mutations, particularly with the substitution Leu421Pro in ponA (39.0%). Mutations affecting the influx and efflux of drugs were also found, including amino acid substitutions in PorB (26.8% isolates) and delA in the promoter region of mtrR (22.8%). The accumulation of mutations in chromosomal genes (penA, pon, porA, and mtrR) led to a stepwise increase in MICpen to values characteristic of intermediate resistance. The presence of blaTEM plasmids was found in 25 isolates (4.8%), resulting in a strong increase in resistance to penicillin (MICpen > 16 mg/L) compared with the chromosomal mutations; 23 plasmids were of the African type with TEM-1 beta-lactamase, and two plasmids were of the Toronto/Rio type with TEM-135 beta-lactamase. Only three isolates were found with reduced susceptibility to ceftriaxone, with MICcef = 0.12–0.25 mg/L. Sequencing of penA did not reveal mutations associated with resistance to third-generation cephalosporins, and the gene structure was non-mosaic. The majority of isolates (21 of 25) carrying the blaTEM plasmid also contained the conjugative plasmid with tetM (resistance to tetracyclines), consistent with previously reported data that the presence of the conjugative plasmid facilitates the transfer of other plasmids associated with antimicrobial resistance.